These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 16461567)

  • 1. Serum HER-2 concentration in patients with primary breast cancer.
    Kong SY; Kang JH; Kwon Y; Kang HS; Chung KW; Kang SH; Lee DH; Ro J; Lee ES
    J Clin Pathol; 2006 Apr; 59(4):373-6. PubMed ID: 16461567
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Serum HER-2 determination using a centauer HER-2/neu kit (CLIA method) in metastatic breast cancer].
    Kan N; Yoshikawa S
    Gan To Kagaku Ryoho; 2009 May; 36(5):779-83. PubMed ID: 19461177
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Serum her-2/neu level and related factors in patients with breast cancer].
    Yuan P; Xu BH; Zhang C; Qi J
    Zhonghua Zhong Liu Za Zhi; 2003 Nov; 25(6):573-4. PubMed ID: 14690565
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tissue expression and serum levels of the oncoprotein HER-2/neu in 157 primary breast tumours.
    Pallud C; Guinebretiere JM; Guepratte S; Hacene K; Neumann R; Carney W; Pichon MF
    Anticancer Res; 2005; 25(2B):1433-40. PubMed ID: 15865102
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HER-2 gene amplification, HER-2 and epidermal growth factor receptor mRNA and protein expression, and lapatinib efficacy in women with metastatic breast cancer.
    Press MF; Finn RS; Cameron D; Di Leo A; Geyer CE; Villalobos IE; Santiago A; Guzman R; Gasparyan A; Ma Y; Danenberg K; Martin AM; Williams L; Oliva C; Stein S; Gagnon R; Arbushites M; Koehler MT
    Clin Cancer Res; 2008 Dec; 14(23):7861-70. PubMed ID: 19047115
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FISH for HER-2/neu in breast cancer: standardization makes the difference!
    Gokhale S; Gatalica Z; Mohammad A; Rampy AI; Velagaleti Gopalrao VN
    Indian J Cancer; 2004; 41(4):152-8. PubMed ID: 15659867
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The influence of serum HER-2 levels and HER-2 codon 655 polymorphism on breast cancer outcome.
    Papadopoulou E; Tripsianis G; Anagnostopoulos K; Tentes I; Kakolyris S; Galazios G; Sivridis E; Simopoulos K; Kortsaris A
    Neoplasma; 2008; 55(2):113-21. PubMed ID: 18237248
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elevated serum levels of a c-erbB-2 oncogene product in oral squamous cell carcinoma patients.
    Chen CH; Lin YS; Lin CC; Yang YH; Ho YP; Tsai CC
    J Oral Pathol Med; 2004 Nov; 33(10):589-94. PubMed ID: 15482324
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of chromosome 17 polysomy on HER-2/neu status in breast cancer.
    Hyun CL; Lee HE; Kim KS; Kim SW; Kim JH; Choe G; Park SY
    J Clin Pathol; 2008 Mar; 61(3):317-21. PubMed ID: 17761736
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Frequency of HER-2/neu receptor positivity and its association with other features of breast cancer.
    Naeem M; Nasir A; Aman Z; Ahmad T; Samad A
    J Ayub Med Coll Abbottabad; 2008; 20(3):23-6. PubMed ID: 19610508
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Borderline HER-2 breast cancer cases: histochemical versus real-time PCR analysis and impact of different cut-off values.
    Monego G; Arena V; Maggiano N; Costarelli L; Crescenzi A; Zelano G; Amini M; Capelli A; Carbone A
    Scand J Clin Lab Invest; 2007; 67(4):402-12. PubMed ID: 17558895
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of predictive and prognostic significance of serum TGF-beta1 levels in breast cancer according to HER-2 codon 655 polymorphism.
    Papadopoulou E; Anagnostopoulos K; Tripsianis G; Tentes I; Kakolyris S; Galazios G; Sivridis E; Simopoulos K; Kortsaris A
    Neoplasma; 2008; 55(3):229-38. PubMed ID: 18348656
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HER-2/neu analysis in breast cancer bone metastases.
    Zustin J; Boddin K; Tsourlakis MC; Burandt E; Mirlacher M; Jaenicke F; Izbicki J; Ruether W; Rueger JM; Bokemeyer C; Simon R; Sauter G
    J Clin Pathol; 2009 Jun; 62(6):542-6. PubMed ID: 19474354
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum EGFR and serum HER-2/neu are useful predictive and prognostic markers in metastatic breast cancer patients treated with metronomic chemotherapy.
    Sandri MT; Johansson HA; Zorzino L; Salvatici M; Passerini R; Maisonneuve P; Rocca A; Peruzzotti G; Colleoni M
    Cancer; 2007 Aug; 110(3):509-17. PubMed ID: 17559147
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum epidermal growth factor receptor/HER-2 predicts poor survival in patients with metastatic breast cancer.
    Souder C; Leitzel K; Ali SM; Demers L; Evans DB; Chaudri-Ross HA; Hackl W; Hamer P; Carney W; Lipton A
    Cancer; 2006 Nov; 107(10):2337-45. PubMed ID: 17048231
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Body mass index and HER-2 overexpression in breast cancer patients over 50 years of age.
    Van Mieghem T; Leunen K; Pochet N; De Moor B; De Smet F; Amant F; Berteloot P; Timmerman D; Vanden Bempt I; Drijkoningen R; Wildiers H; Paridaens R; Smeets A; Hendrickx W; Van Limbergen E; Christiaens MR; Vergote I; Neven P
    Breast Cancer Res Treat; 2007 Nov; 106(1):127-33. PubMed ID: 17211534
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gene expression profiles of breast cancer obtained from core cut biopsies before neoadjuvant docetaxel, adriamycin, and cyclophoshamide chemotherapy correlate with routine prognostic markers and could be used to identify predictive signatures.
    Rody A; Karn T; Gätje R; Kourtis K; Minckwitz G; Loibl S; Munnes M; Ruckhäberle E; Holtrich U; Kaufmann M; Ahr A
    Zentralbl Gynakol; 2006 Apr; 128(2):76-81. PubMed ID: 16673249
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Short-term outcome of primary operated early breast cancer by hormone and HER-2 receptors.
    Brouckaert O; Pintens S; Van Belle V; Van Huffel S; Camerlynck E; Amant F; Leunen K; Smeets A; Berteloot P; Van Limbergen E; Decock J; Hendrickx W; Weltens C; Van den Bogaert W; Vanden Bempt I; Drijkoningen M; Paridaens R; Wildiers H; Vergote I; Christiaens MR; Neven P
    Breast Cancer Res Treat; 2009 May; 115(2):349-58. PubMed ID: 18629635
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Her-2/neu in barrett esophagus: a comparative study between histology, immunohistochemistry, and fluorescence in situ hybridization.
    Rossi E; Villanacci V; Bassotti G; Casa DD; Missale G; Minelli L; Cestari R
    Diagn Mol Pathol; 2006 Sep; 15(3):125-30. PubMed ID: 16932066
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathology of borderline HER-2/neu breast carcinoma: a biologically distinct phenotype.
    Killeen JL; Ortega-Lopez A; Shaha J; Shaha SH; Fu JB
    Breast Cancer Res Treat; 2006 Jul; 98(1):99-108. PubMed ID: 16538540
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.